Lipid-based ELISA test for detection of dairy cattle with Johne`s disease

Award Information
Agency: Department of Agriculture
Branch: N/A
Contract: N/A
Agency Tracking Number: 2010-02810
Amount: $400,000.00
Phase: Phase II
Program: SBIR
Awards Year: 2010
Solicitation Year: N/A
Solicitation Topic Code: 8.3
Solicitation Number: N/A
Small Business Information
4763 WESTRIDGE DR, Fort Collins, CO, 80526
DUNS: 802200399
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Torsten Eckstein
 Research Director
 (970) 223-3203
Business Contact
 Torsten Eckstein
Title: President/CEO
Phone: (970) 223-3203
Research Institution
Johne's disease (JD) is a significant problem in animal health, and this is underscored by its identification by the USDA as the most important infectious disease in ruminants and one of the priority diseases for 2009/2010. Infection with MAP usually occurs after birth and infected calves go through a short period with mild or no symptoms during which they shed the bacteria in feces. This short period, which usually goes unrecognized, is followed by a long incubation period of two to five years in which the animals are presumably healthy, non-shedding, and without any symptoms hinting toward the development of JD. Following the incubation period, MAP-infected cattle develop disease with the characteristic symptoms of chronic diarrhea (with shedding) and weight-loss, loss of milk production, and finally death. There are no specific tools for the prevention or treatment of JD. The only effective control measures are culling the infected animals and/or instituting good herd management practices. Either approach depends on quickly and accurately identifying MAP-infected animals, and separating them from the rest of the herd before they spread the disease through fecal shedding. There is a strong demand from diagnostic laboratories for a test for Johne's disease with no batch-to-batch variation, no extra pre-absorption step, and a higher sensitivity. In this Phase II proposal we present an integrated plan for the final evaluation of the Lipid-ELISA. The proposed experiments will provide essential data on the specificity, sensitivity, stability, and robustness of the Lipid-ELISA assay. The strengths of the Lipid-ELISA as a diagnostic test for Johne's disease are that it is a simpler test without the need for pre-absorption of sera, high reproducibility due to the use of a synthesized lipid antigen, and that it has excellent specificity and better sensitivity than the existing serodiagnostic tests. Eckstein Diagnostics will determine the final sensitivity and specificity of this newly designed diagnostic test for Johne's disease using defined and field study sera from several regions within the US. The test will also be used in a 2-year field study of dairy farms in Northern Colorado. Furthermore, Eckstein Diagnostics will define stability, repeatability, suitability and ruggedness of the diagnostic test kit. Eckstein Diagnostics will file for a sales license with USDA for the US. The licensed diagnostic test will be made available for purchase. It is anticipated that licenses will be obtained in the USA and Canada, several countries within the European Union (Germany, France, Great Britain, Ireland, Spain, Greece, Italy, and The Netherlands), as well as in Australia and New Zealand. The test will be used within the latter countries for sheep instead of cattle.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government